{"id":859328,"date":"2026-08-15T18:58:11","date_gmt":"2026-08-15T18:58:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/859328\/"},"modified":"2026-08-15T18:58:11","modified_gmt":"2026-08-15T18:58:11","slug":"pablo-nenclares-pemda-hn-trial-reports-final-results-on-danvatirsen-plus-pembrolizumab","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/859328\/","title":{"rendered":"Pablo Nenclares: PEMDA-HN Trial Reports Final Results on Danvatirsen Plus Pembrolizumab"},"content":{"rendered":"<p> Pablo Nenclares, Consultant Clinical Oncologist at Barts Health NHS Trust and Honorary Associate Professor at UCL, shared on <a href=\"https:\/\/www.linkedin.com\/posts\/pablo-nenclares-541330167_headandneckcancer-clinicaltrials-cancerresearch-share-7492982299035168768-7gSy\/?utm_source=share&amp;utm_medium=member_desktop&amp;rcm=ACoAAFjOREkBNl14rwPMnasF2Wisrz-2trK3b1Q\" target=\"_blank\" rel=\"noopener nofollow\">LinkedIn<\/a>:<\/p>\n<p>\u201cPleased to see the final results of the PEMDA-HN study recently published in the IJROBP, The Red Journal<\/p>\n<p>This international, multicentre phase II trial evaluated danvatirsen plus pembrolizumab versus pembrolizumab alone as first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.<\/p>\n<p>While the combination did not improve response rates compared with pembrolizumab alone, the study provides an important reminder of the value of well-designed randomised clinical trials \u2013 including when the results are not what we hoped for.<\/p>\n<p>At <a href=\"https:\/\/oncodaily.com\/tag\/barts-cancer-institute\" rel=\"nofollow noopener\" target=\"_blank\">Barts Cancer Institute<\/a> (Queen Mary University of London), we were proud to contribute to this collaborative effort and to the generation of evidence that helps guide future research and treatment strategies in head and neck cancer.<\/p>\n<p>Congratulations to all investigators, research teams, and, most importantly, the patients who made this study possible.\u201d<\/p>\n<p>Title:\u00a0Danvatirsen Plus Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PEMDA-HN): Final Results of a Randomized Phase 2 Trial<\/p>\n<p>Authors:\u00a0D.J. Wong, K. Harrington, P. Neupane, P. Nenclares, M. Mirsky, L. Makris, S. Macintyre, A.E. Denker, M. Posner, N.F. Saba<\/p>\n<p>Read the <a href=\"https:\/\/www.redjournal.org\/article\/S0360-3016(26)00184-7\/abstract\" target=\"_blank\" rel=\"noopener nofollow\">Full Article<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-567005 aligncenter\" src=\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2026\/08\/Screenshot-2026-08-15-at-18.44.26-800x161.webp\" alt=\"Pablo Nenclares\" width=\"800\" height=\"161\" title=\"Pablo Nenclares: PEMDA-HN Trial Reports Final Results on Danvatirsen Plus Pembrolizumab 2\"  \/><\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Pablo Nenclares, Consultant Clinical Oncologist at Barts Health NHS Trust and Honorary Associate Professor at UCL, shared on&hellip;\n","protected":false},"author":2,"featured_media":859329,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[49,48,61],"class_list":["post-859328","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology","tag-ca","tag-canada","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/859328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=859328"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/859328\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/859329"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=859328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=859328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=859328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}